Charles-Schoeman C, et al. – Researchers performed data analysis to investigate the risk of major adverse cardiovascular events (MACE) in tofacitinib-treated patients with rheumatoid arthritis. Over 12,873 patient-years of exposure, 52 MACE occurred among 4,076 patients, with an incidence rate of 0.4 patients with events/100 patient-years. Upon univariable analyses of baseline variables, they investigators noted that traditional cardiovascular risk factors, as well as corticosteroid and stain use were associated with risk of MACE. Disease activity and inflammation measures, however, were not. Baseline age, hypertension, and TC/HDL-c were significantly correlated with the risk of MACE in subsequent multivariable analyses. The researchers also noted an association of HDL-c increases and TC/HDL-c decreases with decreased MACE risk after 24 weeks of tofacitinib treatment.